Abstract #3581

Imaging Treatment Response with Hyperpolarized Pyruvate in Anaplastic Thyroid Carcinoma

Christopher M Walker¹, Zhan Xu¹, Keith Michel¹, Gary Martinez¹, Collin J. Harlan¹, Jeremy W. Gordon², Stephanie Carlon¹, Sandra Williams¹, Freddy Gonzalez¹, Stacy Hash¹, Jerell Jones¹, Asa McCoy¹, Brandy Willis¹, Michelle Underwood¹, Andrew Day³, Moin Chariwala³, Dao Le⁴, Gregory Waligorski³, Daniel B. Vigneron², Dawid Schellingerhout⁵, Stephen Y. Lai⁶, and James A. Bankson¹

¹Imaging Physics, MD Anderson Cancer Center, Houston, TX, United States, ²2. Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, San Francisco, CA, United States, ³Center for Advanced Biomedical Imaging, MD Anderson Cancer Center, Houston, TX, United States, ⁴Nuclear Medicine, MD Anderson Cancer Center, Houston, TX, United States, ⁵Nueroradiology, MD Anderson Cancer Center, Houston, TX, United States, ⁶Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, United States

This case report presents the detection of hyperpolarized lactate production in a patient with anaplastic thyroid carcinoma. Lactate signal was observed following injection of hyperpolarized pyruvate and the signal was well localized to the tumor. The normalized lactate signal was reduced eight days following the onset of systemic therapy with Pembro and Lenvatinib.

This abstract and the presentation materials are available to members only; a login is required.

Join Here